Myoclonic Epilepsy Latest Advances

Clinical Reasoning: A 5-year-Old Boy With Subacute and Refractory Myoclonus.

Journal: Neurology

Published: December 03, 2025

Relieving the Weight: Fenfluramine's Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome.

Journal: The Annals of pharmacotherapy

Published: December 01, 2025

Epilepsy-associated Variants of a Single SCN1A Codon exhibit Divergent Functional Properties.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Correction to "Metabolomic signature of the Dravet syndrome: A genetic mouse model study".

Journal: Epilepsia

Published: November 21, 2025

ERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies.

Journal: Neurochemistry international

Published: November 21, 2025

Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study.

Journal: Developmental medicine and child neurology

Published: November 18, 2025

Flip of the Switch: Targeting GABA Dysregulation to Treat Nonseizure Comorbidities in Dravet Syndrome.

Journal: Epilepsy currents

Published: November 17, 2025

Natural History of Children and Adolescents With Dravet Syndrome: A 24-Month Follow-Up.

Journal: Neurology

Published: November 14, 2025

Juvenile Myoclonic Epilepsy in Children and Adolescents: The Effect of Antiseizure Medications on Cognitive Functions.

Journal: Journal of child neurology

Published: November 06, 2025

Dravet syndrome therapeutics: where are we, what works, and what's next?

Journal: Expert opinion on pharmacotherapy

Published: October 20, 2025

α-Asaronol, a low-toxicity α-asarone metabolite, suppresses seizures in zebrafish Dravet syndrome via positive modulation of GABAA receptors and LDH inhibition.

Journal: Neuropharmacology

Published: October 13, 2025

New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: October 13, 2025

Filters

Clinical Reasoning: A 5-year-Old Boy With Subacute and Refractory Myoclonus.

Clinical Reasoning: A 5-year-Old Boy With Subacute and Refractory Myoclonus.

Relieving the Weight: Fenfluramine's Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome.

Relieving the Weight: Fenfluramine's Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome.

Epilepsy-associated Variants of a Single SCN1A Codon exhibit Divergent Functional Properties.

Epilepsy-associated Variants of a Single SCN1A Codon exhibit Divergent Functional Properties.

Correction to "Metabolomic signature of the Dravet syndrome: A genetic mouse model study".

Correction to "Metabolomic signature of the Dravet syndrome: A genetic mouse model study".

ERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies.

ERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies.

Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study.

Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study.

Flip of the Switch: Targeting GABA Dysregulation to Treat Nonseizure Comorbidities in Dravet Syndrome.

Flip of the Switch: Targeting GABA Dysregulation to Treat Nonseizure Comorbidities in Dravet Syndrome.

Natural History of Children and Adolescents With Dravet Syndrome: A 24-Month Follow-Up.

Natural History of Children and Adolescents With Dravet Syndrome: A 24-Month Follow-Up.

Juvenile Myoclonic Epilepsy in Children and Adolescents: The Effect of Antiseizure Medications on Cognitive Functions.

Juvenile Myoclonic Epilepsy in Children and Adolescents: The Effect of Antiseizure Medications on Cognitive Functions.

Dravet syndrome therapeutics: where are we, what works, and what's next?

Dravet syndrome therapeutics: where are we, what works, and what's next?

α-Asaronol, a low-toxicity α-asarone metabolite, suppresses seizures in zebrafish Dravet syndrome via positive modulation of GABAA receptors and LDH inhibition.

α-Asaronol, a low-toxicity α-asarone metabolite, suppresses seizures in zebrafish Dravet syndrome via positive modulation of GABAA receptors and LDH inhibition.

New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment.

New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment.